$CODX
Co-Diagnostics Inc Stock $codx

$codx Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000149315223007925 Filed on March 16, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$602.0K	$1.401M	$34.22M
YoY Change	-97.35%	-93.13%	-65.04%
Cost Of Revenue	$502.2K	$515.8K	$5.481M
YoY Change	-84.7%	-79.26%	-52.65%
Gross Profit	$99.72K	$885.7K	$28.74M
YoY Change	-99.49%	-95.06%	-66.71%
Gross Profit Margin	16.57%	63.2%	83.98%
Selling, General & Admin	$4.720M	$6.580M	$21.61M
YoY Change	-15.32%	23.67%	-12.86%
% of Gross Profit	4733.74%	742.95%	75.19%
Research & Development	$5.014M	$4.739M	$17.44M
YoY Change	32.95%	117.17%	16.55%
% of Gross Profit	5028.34%	535.1%	60.68%
Depreciation & Amortization	$316.0K	$298.6K	$1.283M
YoY Change	27.8%	191.05%	282.49%
% of Gross Profit	316.91%	33.72%	4.46%
Operating Expenses	$10.05M	$11.62M	$55.72M
YoY Change	4.77%	52.76%	38.96%
Operating Profit	-$9.951M	-$10.73M	-$26.98M
YoY Change	-201.29%	-204.11%	-158.38%
Interest Expense	$897.8K	$256.7K	$371.1K
YoY Change	-9122.91%	-1378.59%	-196.43%
% of Operating Profit
Other Income/Expense, Net	$1.935M		$8.133M
YoY Change	-40.93%		-1995.02%
Pretax Income	-$8.015M	-$25.04M	-$18.85M
YoY Change	-161.18%	-344.47%	-141.3%
Income Tax	-$2.260M	-$3.139M	-$4.609M
% Of Pretax Income
Net Earnings	-$5.755M	-$21.91M	-$14.24M
YoY Change	-149.13%	-392.13%	-138.84%
Net Earnings / Revenue	-956.11%	-1563.02%	-41.61%
Basic Earnings Per Share	-$0.20		-$0.45
Diluted Earnings Per Share	-$0.20	-$0.74	-$0.45
COMMON SHARES
Basic Shares Outstanding	30.92M shares	30.92M shares	31.48M shares
Diluted Shares Outstanding	29.48M shares		31.48M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$75.28M	$81.26M	$81.26M
YoY Change	-22.73%	-9.57%	-9.57%
Cash & Equivalents	$6.359M	$22.97M
Short-Term Investments	$68.92M	$58.29M	$58.29M
Other Short-Term Assets	$913.2K	$761.2K	$761.2K
YoY Change	-32.54%	-68.46%	-68.46%
Inventory	$5.295M	$5.310M	$5.310M
Prepaid Expenses
Receivables	$2.702M	$3.454M	$3.454M
Other Receivables	$1.733M	$1.945M	$1.945M
Total Short-Term Assets	$85.92M	$92.73M	$92.73M
YoY Change	-31.45%	-19.45%	-19.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.510M	$2.539M	$2.912M
YoY Change	-12.16%	31.36%	50.61%
Goodwill
YoY Change
Intangibles	$26.66M	$26.77M
YoY Change		-1.57%
Long-Term Investments	$950.0K	$672.7K	$672.7K
YoY Change	-3.42%	-33.06%	-33.06%
Other Assets
YoY Change
Total Long-Term Assets	$31.07M	$30.35M	$30.35M
YoY Change	-32.17%	-32.42%	-32.42%
TOTAL ASSETS
Total Short-Term Assets	$85.92M	$92.73M	$92.73M
Total Long-Term Assets	$31.07M	$30.35M	$30.35M
Total Assets	$117.0M	$123.1M	$123.1M
YoY Change	-31.64%	-23.09%	-23.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$829.8K	$952.3K	$952.3K
YoY Change	-31.7%	56.76%	56.75%
Accrued Expenses	$1.493M	$934.4K	$1.232M
YoY Change	-48.47%	-75.79%	-68.09%
Deferred Revenue	$18.12K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.610M	$3.873M	$3.873M
YoY Change	-72.27%	-69.25%	-69.25%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.554M	$2.275M	$2.275M
YoY Change	-43.85%	-60.32%	-60.32%
Total Long-Term Liabilities	$2.757M	$4.693M	$2.275M
YoY Change	-39.37%	-63.79%	-60.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.610M	$3.873M	$3.873M
Total Long-Term Liabilities	$2.757M	$4.693M	$2.275M
Total Liabilities	$6.367M	$8.566M	$8.566M
YoY Change	-72.83%	-66.48%	-66.48%
SHAREHOLDERS EQUITY
Retained Earnings	$34.18M	$39.93M
YoY Change		-26.28%
Common Stock	$34.82K	$34.75K
YoY Change		2.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$14.69M	$14.21M
YoY Change
Treasury Stock Shares		3.882M shares
Shareholders Equity	$110.6M	$114.5M	$114.5M
YoY Change
Total Liabilities & Shareholders Equity	$117.0M	$123.1M	$123.1M
YoY Change	-31.64%	-23.09%	-23.09%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$5.755M	-$21.91M	-$14.24M
YoY Change	-149.13%	-392.13%	-138.84%
Depreciation, Depletion And Amortization	$316.0K	$298.6K	$1.283M
YoY Change	27.8%	191.05%	282.49%
Cash From Operating Activities	-$5.499M	-$4.010M	$6.569M
YoY Change	-170.45%	-182.19%	-84.01%
INVESTING ACTIVITIES
Capital Expenditures	$179.9K	$293.3K	$1.428M
YoY Change	-145.37%	-340.9%	-313.23%
Acquisitions
YoY Change
Other Investing Activities	-$10.45M	-$53.01M	-$56.74M
YoY Change	-932.72%	-4546.48%	-1289.99%
Cash From Investing Activities	-$10.63M	-$53.31M	-$58.17M
YoY Change	-1338.29%	-5079.58%	-1519.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$14.03M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$482.2K	-1.218M	-$14.03M
YoY Change	-421.46%		-3215.9%
NET CHANGE
Cash From Operating Activities	-$5.499M	-4.010M	$6.569M
Cash From Investing Activities	-$10.63M	-53.31M	-$58.17M
Cash From Financing Activities	-$482.2K	-1.218M	-$14.03M
Net Change In Cash	-$16.61M	-58.53M	-$65.63M
YoY Change	-288.49%	-1083.94%	-243.84%
FREE CASH FLOW
Cash From Operating Activities	-$5.499M	-$4.010M	$6.569M
Capital Expenditures	$179.9K	$293.3K	$1.428M
Free Cash Flow	-$5.679M	-$4.303M	$5.141M
YoY Change	-169.24%	-186.06%	-87.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001692415
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable		usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent		usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax		usd
CY2021	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax		usd
CY2021	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2021	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies		usd
CY2021	CODX	Noncash Lease Expense NoncashLeaseExpense		usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture		usd
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2021Q4	CODX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2021	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments		usd
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2022Q4	us-gaap	Goodwill Goodwill		usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability		usd
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment		shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2021	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2021	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2021	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2021	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures		shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeitedWeightedAverageGrantDateFairValue
CY2021Q4	CODX	Deferred Tax Assets Uniform Capitalization DeferredTaxAssetsUniformCapitalization		usd
CY2021Q4	CODX	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset		usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance		usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment		usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal		usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions		usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive		usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38148
CY2022	dei	Entity Registrant Name EntityRegistrantName	CO-DIAGNOSTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	UT
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-2609396
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	2401 S. Foothill Drive
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Salt Lake City
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	UT
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	84109
CY2022	dei	City Area Code CityAreaCode	(801)
CY2022	dei	Local Phone Number LocalPhoneNumber	438-1036
CY2022	dei	Security12b Title Security12bTitle	Common Stock
CY2022	dei	Trading Symbol TradingSymbol	CODX
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	187000000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30922607	shares
CY2022	dei	Auditor Firm AuditorFirmId	457
CY2022	dei	Auditor Name AuditorName	Haynie & Company
CY2022	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88607234	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	58289066	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	1255266	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	1870419	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	761186	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2338444	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	75000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	92733670	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	115119295	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1933216	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	372115	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
CY2022Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	672679	usd
CY2021Q4	us-gaap	Real Estate Investments Joint Ventures RealEstateInvestmentsJointVentures	1004953	usd
CY2021Q4	us-gaap	Notes And Loans Receivable Net Noncurrent NotesAndLoansReceivableNetNoncurrent	75000	usd
CY2022Q4	us-gaap	Assets Assets	123086280	usd
CY2021Q4	us-gaap	Assets Assets	160034282	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	952297	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	607506	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3859652	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297209	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	1689471	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Current AssetAcquisitionContingentConsiderationLiabilityCurrent	5767304	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2213088	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	150000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3873424	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	12597550	usd
CY2022Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1181284	usd
CY2021Q4	CODX	Taxes Payable Noncurrent TaxesPayableNoncurrent	1067853	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	2417987	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7228444	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50708	usd
CY2022Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	1042885	usd
CY2021Q4	us-gaap	Asset Acquisition Contingent Consideration Liability Noncurrent AssetAcquisitionContingentConsiderationLiabilityNoncurrent	4665337	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4692864	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12961634	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8566288	usd
CY2021Q4	us-gaap	Liabilities Liabilities	25559184	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34754265	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30872607	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33819862	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33819862	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	34754	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	33820	usd
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3881658	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	14211866	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	88472934	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	80271999	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	39931030	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	54169279	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519992	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	123086280	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	160034282	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	34218209	usd
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	97885603	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	5481092	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	11574944	usd
CY2022	us-gaap	Gross Profit GrossProfit	28737117	usd
CY2021	us-gaap	Gross Profit GrossProfit	86310659	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7344628	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13397813	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14262963	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11550615	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17438098	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14961916	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1282718	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	335363	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	55716953	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	40245707	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-26979836	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	46064952	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	704044	usd
CY2021	us-gaap	Interest Income Other InterestIncomeOther	45631	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44355	usd
CY2022	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7899644	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-332969	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-430433	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8132602	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-429157	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18847234	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	45635795	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4608985	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8977231	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	36658564	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	293140	usd
CY2022	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	293140	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13945109	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	36658564	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31479028	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28874555	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31479028	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29903686	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	66696509	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	450398	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	5509404	usd
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	25160223	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	36658564	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	134475098	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	77870	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	7543223	usd
CY2022	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	480776	usd
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	14211866	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	293140	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519992	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	114519992	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	36658564	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1282718	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	335363	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	7543223	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	5509404	usd
CY2022	CODX	Gain On Remeasurement Of Acquisition Contingencies GainOnRemeasurementOfAcquisitionContingencies	7899644	usd
CY2022	CODX	Noncash Lease Expense NoncashLeaseExpense	30430	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-332969	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	-430433	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-138117	usd
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-44355	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4810457	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	930081	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2428930	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	69672	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-14956529	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8740851	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	224094	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	2049095	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3525210	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5705361	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-150000	usd
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-155307	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-2201250	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	2643381	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2483821	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-299937	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	6568737	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	41081424	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1427512	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	669463	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	11255266	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3080180	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	67995926	usd
CY2021	us-gaap	Proceeds From Divestiture Of Interest In Joint Venture ProceedsFromDivestitureOfInterestInJointVenture	491739	usd
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	-1196243	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58168172	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4098699	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	177870	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	450398	usd
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	14211866	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-14033996	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	450398	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-65633431	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	45630521	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	42976713	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22973803	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	88607234	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4498742	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	5403769	usd
CY2022	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	218906	usd
CY2021	CODX	Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment	285659	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	681327	usd
CY2022	CODX	Business Acquisition Measurement Period Adjustments BusinessAcquisitionMeasurementPeriodAdjustments	1593	usd
CY2022	CODX	Stock Issued During Period Value Acquisitions Adjustments StockIssuedDuringPeriodValueAcquisitionsAdjustments	480776	usd
CY2021	CODX	Stock Issued During Period Value Acquisitions Adjustments StockIssuedDuringPeriodValueAcquisitionsAdjustments	25160223	usd
CY2022	CODX	Fair Value Of Contingent Common Stock And Warrants Issued As Consideration For Business Acquisitions FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions	199359	usd
CY2021	CODX	Fair Value Of Contingent Common Stock And Warrants Issued As Consideration For Business Acquisitions FairValueOfContingentCommonStockAndWarrantsIssuedAsConsiderationForBusinessAcquisitions	10432641	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	5310473	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1327264	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3983209	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	6552249	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3098526	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3453723	usd
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	21508779	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	669597	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20839182	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	2004169	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	983088	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1021081	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	15388546	usd
CY2020Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	5.21
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1	P3Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	456281	shares
CY2021	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice	9.13
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue	3.83
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17438098	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14961916	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	526281	shares
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_848_eus-gaap--ConcentrationRiskCreditRisk_zBLAQRjUUgI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zvToWzpxpSEc">Concentrations Risk and Significant Customers</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company had certain customers which are each responsible for generating <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zkUQi3pu6Tv3" title="Concentration risk percentage"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zX6u0Rm6gmJh" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the years ended December 31, 2022 and 2021. One customer accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUjMqCAI0uY2" title="Concentration risk percentage"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--OneCustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQ7C3WjRK7t1" title="Concentration risk percentage">37</span></span>% and two customers together accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSiBVLz4t8q5" title="Total revenue, percentage"><span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--TwoCustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zq9Skfg7W0Eb" title="Total revenue, percentage">48</span></span>% of total revenue for the years ended December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Three customers accounted for more than <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zzNino7otFNi" title="Concentration risk percentage">10</span>% of accounts receivable, and two customers each accounted for more than <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--FourCustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zNDIuMuno5c2" title="Concentration risk percentage">10</span>% of accounts receivable, at December 31, 2022 and 2021, respectively. These customers together accounted for approximately <span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zn9o5cgE2otl" title="Concentration risk percentage">61</span>% and <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zLDBKw7sEXA4" title="Concentration risk percentage">66</span>% of accounts receivable at December 31, 2022 and 2021, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4	us-gaap	Trading Securities Debt Amortized Cost TradingSecuritiesDebtAmortizedCost	80873628	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	389241	usd
CY2022Q4	us-gaap	Trading Securities TradingSecurities	81262869	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22973803	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	58289066	usd
CY2022Q4	CODX	Remeasurement Of Acquisition Contingencies RemeasurementOfAcquisitionContingencies	78617	usd
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10432641	usd
CY2022	CODX	Contingent Considered Issued For Measurement Period Adjustments ContingentConsideredIssuedForMeasurementPeriodAdjustments	199359	usd
CY2022	CODX	Contingent Considered Issued For Business Acquisitions ContingentConsideredIssuedForBusinessAcquisitions	-7899644	usd
CY2022Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2732356	usd
CY2022Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P4Y
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1372248	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	622155	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2539483	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1933216	usd
CY2021Q4	us-gaap	Goodwill Goodwill	14706818	usd
CY2022	us-gaap	Goodwill Translation And Purchase Accounting Adjustments GoodwillTranslationAndPurchaseAccountingAdjustments	681728	usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	15388546	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	-426667	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26768333	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	27195000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	27195000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	364668	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	302665	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	667333	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	70000	shares
CY2020Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	1.83
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	428354	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	2455694	usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	159725	usd
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	509500	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	346368	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	894458	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	934447	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3859652	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34218209	usd
CY2021	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	97885603	usd
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	305307	usd
CY2021	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	256110	usd
CY2021	CODX	Increase Due To Prepayments From Customers IncreaseDueToPrepaymentsFromCustomers	79213	usd
CY2021	CODX	Increase Due To Note Receivable IncreaseDueToNoteReceivable	150000	usd
CY2021	CODX	Decrease Due To Refunds To Customers And Application To Open Balances DecreaseDueToRefundsToCustomersAndApplicationToOpenBalances	128410	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	150000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	150000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14238249	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	36658564	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	31479028	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28874555	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	1029131	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	31479028	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29903686	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.27
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.45
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	154644	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	0	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1300588	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.44
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.24
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	189225	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.38
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised	1.12
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1111363	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.12
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.31
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	70791	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.10
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised	0.51
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1040572	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.19
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	1.37
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm	P5Y10M17D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1040572	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.19
CY2022Q4	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable	1.37
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y10M17D
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice	8.15
CY2021Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue	4.01
CY2021	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y8M12D
CY2022	CODX	Share Based Compensation Issued For Adjustments To Contingent Purchase Consideration ShareBasedCompensationIssuedForAdjustmentsToContingentPurchaseConsideration	8719	shares
CY2022	CODX	Issued For Adjustments To Contingent Purchase Consideration Period Weighted Average Exercise Price IssuedForAdjustmentsToContingentPurchaseConsiderationPeriodWeightedAverageExercisePrice	9.13
CY2022	CODX	Issued For Adjustments To Contingent Purchase Consideration Weighted Average Grant Date Fair Value IssuedForAdjustmentsToContingentPurchaseConsiderationWeightedAverageGrantDateFairValue	1.88
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	50000	shares
CY2022	CODX	Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice	2.00
CY2022	CODX	Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.22
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	485000	shares
CY2022Q4	CODX	Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice	8.81
CY2022Q4	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue	2.43
CY2022	CODX	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term3 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm3	P4Y
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	456000	shares
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7543223	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5509404	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	563821	usd
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6092730	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-266248	usd
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	886173	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	297573	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	6978903	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3945090	usd
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1394686	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-961468	usd
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	603642	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-4906558	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	1998328	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4608985	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8977231	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.048	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Foreignderived Intangible Income Deduction EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction	0.014	pure
CY2021	CODX	Effective Income Tax Rate Reconciliation Foreignderived Intangible Income Deduction EffectiveIncomeTaxRateReconciliationForeignderivedIntangibleIncomeDeduction	-0.035	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.036	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.002	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Contingent Consideration Remeasurement EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement	0.088	pure
CY2021	CODX	Effective Income Tax Rate Reconciliation Contingent Consideration Remeasurement EffectiveIncomeTaxRateReconciliationContingentConsiderationRemeasurement	0.000	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	-0.171	pure
CY2021	CODX	Effective Income Tax Rate Reconciliation Goodwill Impairment EffectiveIncomeTaxRateReconciliationGoodwillImpairment	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.006	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.003	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	-0.111	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.026	pure
CY2022	CODX	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	-0.021	pure
CY2021	CODX	Effective Income Tax Rate Reconciliation Change In Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInValuationAllowance	0.014	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.000	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.008	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.010	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.245	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.197	pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	98141	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	765004	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	166050	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	566076	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	393871	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3460159	usd
CY2022Q4	CODX	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	85899	usd
CY2022Q4	CODX	Deferred Tax Assets Uniform Capitalization DeferredTaxAssetsUniformCapitalization	168936	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	5144215	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	559921	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	609261	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	477542	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6608914	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6743972	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	156053	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	560093	usd
CY2022Q4	CODX	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	-91873	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Other Comprehensive Income DeferredTaxLiabilitiesOtherComprehensiveIncome	96101	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	6758	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7562202	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7788365	usd
CY2022Q4	CODX	Net Deferred Tax Liabilities NetDeferredTaxLiabilities	-2417987	usd
CY2021Q4	CODX	Net Deferred Tax Liabilities NetDeferredTaxLiabilities	-7228444	usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	2417987	usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	7228444	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	288292	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1469577	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1067853	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1067853	usd
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	447831	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1045590	usd
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	770069	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	34035	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	677901	usd
CY2021	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	150047	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1469577	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1067853	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	34035	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	346349	usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost	384902	usd
CY2022	us-gaap	Lease Cost LeaseCost	731251	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	303059	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	50773	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	353832	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5915	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	347917	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297209	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	50708	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	700821	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031	pure
CY2022Q1	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	30000000.0	usd
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	-0	shares
CY2022	CODX	Repurchases Of Common Stock RepurchasesOfCommonStock	3881658	shares
CY2022Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	3881658	shares

Files In Submission

Name	View Source	Status
form10-k_htm.xml	Edgar Link	completed
0001493152-23-007925-index-headers.html	Edgar Link	pending
0001493152-23-007925-index.html	Edgar Link	pending
0001493152-23-007925.txt	Edgar Link	pending
0001493152-23-007925-xbrl.zip	Edgar Link	pending
codx-20221231.xsd	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
codx-20221231_cal.xml	Edgar Link	unprocessable
codx-20221231_def.xml	Edgar Link	unprocessable
codx-20221231_lab.xml	Edgar Link	unprocessable
codx-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CODX
Co-Diagnostics Inc Stock $codx

2023 Q1 Form 10-K Financial Statement

#000149315223007925 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX Co-Diagnostics Inc Stock $codx

2023 Q1 Form 10-K Financial Statement

#000149315223007925 Filed on March 16, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CODX
Co-Diagnostics Inc Stock $codx